Apellis reports mixed data with eye drug, but plans to file anywayApellis Pharma has reported mixed results with its lead drug pegcetacoplan in geographic atrophy (GA) – a major Share XApellis reports mixed data with eye drug, but plans to file anywayhttps://pharmaphorum.com/news/apellis-reports-mixed-data-with-eye-drug-but-plans-to-file-anyway/
Apellis set to take on Alexion as FDA clears PNH drug EmpaveliApellis Pharma has secured FDA approval for its complement C3 inhibitor Empaveli as a treatment for paroxysmal nocturnal Share XApellis set to take on Alexion as FDA clears PNH drug Empavelihttps://pharmaphorum.com/news/apellis-set-to-take-on-alexion-as-fda-clears-pnh-drug-empaveli/
